Illumina, Inc. $ILMN Shares Purchased by Jump Financial LLC

Key Points

• Jump Financial LLC increased its position in Illumina, Inc. by 919.0% in Q1, totaling 80,147 shares valued at approximately $6.36 million.
• Illumina's current consensus rating is "Hold" with a target price of $124.58, reflecting varied analyst perceptions including upgrades and downgrades.
• In its most recent earnings report, Illumina reported $1.19 EPS, exceeding expectations but with a 4.8% year-over-year revenue decline.

Jump Financial LLC lifted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 919.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,147 shares of the life sciences company's stock after buying an additional 72,282 shares during the period. Jump Financial LLC owned about 0.05% of Illumina worth $6,359,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ILMN. Moors & Cabot Inc. lifted its position in shares of Illumina by 2.5% in the 1st quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock worth $465,000 after purchasing an additional 145 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Illumina by 3.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock worth $445,000 after purchasing an additional 164 shares during the period. Probity Advisors Inc. lifted its position in shares of Illumina by 12.2% in the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after purchasing an additional 224 shares during the period. Xponance Inc. lifted its position in shares of Illumina by 1.0% in the 1st quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock worth $2,123,000 after purchasing an additional 264 shares during the period. Finally, Rakuten Securities Inc. lifted its position in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after purchasing an additional 270 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ILMN. Citigroup cut shares of Illumina from a "hold" rating to a "strong sell" rating and lowered their price target for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Evercore ISI increased their target price on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Piper Sandler decreased their target price on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. Scotiabank cut shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price for the company. in a research report on Friday, July 11th. Finally, Daiwa America cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 12th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Illumina currently has an average rating of "Hold" and an average target price of $123.17.

Illumina Stock Performance

Shares of NASDAQ ILMN traded up $0.84 during midday trading on Friday, reaching $100.01. The company had a trading volume of 558,985 shares, compared to its average volume of 2,304,699. The business's 50-day simple moving average is $98.91 and its 200 day simple moving average is $88.67. The stock has a market cap of $15.37 billion, a P/E ratio of 12.66, a P/E/G ratio of 2.24 and a beta of 1.37. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business's quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter last year, the company posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.